What are the early warning signs of Progressive Supranuclear Palsy? New UK Biobank research identifies depression, gut issues, and delirium as precursors to PSP.

Is paternal postnatal depression delayed? New research finds a 30% increase in depression and stress diagnoses for fathers ...

Alto Neuroscience secures $120M to advance novel depression therapy ALTO-207 through Phase 3 trials, aiming for FDA ...

On Tuesday, Alto Neuroscience, Inc. (NASDAQ:ANRO) announced an asset purchase agreement with Chase Therapeutics Corporation for a portfolio of dopamine agonist drug combinations for ...

In a major shift for how mental health conditions might be treated, the US Food and Drug Administration (FDA) has approved the first at-home brain-stimulation device to treat moderate to severe major ...

Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported ...

An AI-based machine learning tool identified depression in 71% of people with the condition from under a minute of free speech. The findings may enable more widespread screening for the condition. The ...

People with depression tend to prefer carbohydrate-rich foods, according to a new study published in Psychological Medicine. The findings point toward the possibility of dietary therapies for ...

Alto Neuroscience (ANRO) has announced a private placement financing (PIPE) agreement to raise approximately $120 million before expenses. The financing is led by Commodore Capital with support from ...

Neuropsychiatric drug development is rife with clinical trial failures, but Alto Neuroscience aims to overcome these hurdles with a precision medicine approach that matches a patient to a drug. A ...